BioCentury
ARTICLE | Company News

Aixlie, Ohio State University deal

January 16, 2001 8:00 AM UTC

Aixlie received an exclusive license from the university to a HER-2 cancer vaccine and a peptide that regulates CD28. The vaccine is in Phase I testing to treat cancer, and the peptide is in preclini...